MRTX - Mirati Therapeutics GAAP EPS of -$3.09 beats by $0.40 revenue of $5.4M beats by $4.03M
- Mirati Therapeutics press release ( NASDAQ: MRTX ): Q3 GAAP EPS of -$3.09 beats by $0.40 .
- Revenue of $5.4M (-92.5% Y/Y) beats by $4.03M .
- MRTX's revenue of $71.8M in Q3 last year was due to the recognition of $66.6M of revenue associated with the transfer of the license and know-how of adagrasib as part of co's agreement with Zai Lab, and a $5M milestone payment from BeiGene ( BGNE ).
- Cash, cash equivalents, and short-term investments of approximately $1.2B as of Sept. 30, 2022.
For further details see:
Mirati Therapeutics GAAP EPS of -$3.09 beats by $0.40, revenue of $5.4M beats by $4.03M